Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 43, Issue 2, 2007, Pages 763-768

  Kimiskidis, Vasilios ^a   Spanakis, Marios ^a   Niopas, Ioannis ^a   Kazis, Dimitrios ^a   Gabrieli, Chrysi ^a   Kanaze, Feras Imad ^a   Divanoglou, Daniil ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Analytical method validation; HPLC; Metabolite; Oxcarbazepine; Plasma cerebrospinal fluid ratio

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; ANTICONVULSIVE AGENT; DRUG METABOLITE; LICARBAZEPINE; OXCARBAZEPINE;

ACCURACY; ADJUVANT THERAPY; ANALYTIC METHOD; ANTICONVULSANT THERAPY; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLITE; MONOTHERAPY; PLASMA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETONITRILES; AMINES; ANTICONVULSANTS; BIOTRANSFORMATION; BUFFERS; CALIBRATION; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; EPILEPSY; GUIDELINES; HUMANS; LINEAR MODELS; PHOSPHATES; POTASSIUM COMPOUNDS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33845663303     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2006.07.047     Document Type: Article

References (30)

1. Grant S.M., and Faulds D. Drugs 43 (1992) 873-888
2. Baruzzi A., Albani F., and Riva R. Epilepsia 35 (1994) S14-S19
3. Gram L. Epilepsia 37 (1996) S12-S16
4. Fraser A.D. Clin. Biochem. 29 (1996) 97-110
5. Sachdeo R., Beydoun A., Schachter S., Vazquez B., Schaul N., Mesenbrink P., Kramer L., and D'Souza J. Neurology 57 (2001) 864-871
6. Beydoun A., and Kutluay E. Expert Opin. Pharmacother. 3 (2002) 59-71
7. Kalis M.M., and Huff N.A. Clin. Ther. 23 (2001) 680-700
8. Stefani A., Pisani A., De Murtas M., Mercuri N.B., Marciani M.G., and Calabresi P. Epilepsia 36 (1995) 997-1002
9. Faigle J.W., and Menge G.P. Int. Clin. Psychopharmacol. 5 (1990) 73-82
10. Larkin J.G., McKee P.J.W., Forrest G., Beastall G.H., Park B.K., Lowrie J.I., Lloyd P., and Brodie M.J. Br. J. Clin. Pharmacol. 31 (1991) 65-71
11. Tartara A., Galimberti C.A., Manni R., Morini R., Limido G., Gatti G., Bartoli A., Strada G., and Perucca E. Br. J. Clin. Pharmacol. 36 (1993) 366-368
12. Myllynen P., Pienimaki P., Raunio H., and Vahakangas K. Hum. Exp. Toxicol. 17 (1998) 668-676
13. Hartley R., Green M., Lucock M.D., Ryan S., and Forsythe W.I. Biomed. Chromatogr. 5 (1991) 212-215
14. Pienimaki P., Fuchs S., Isojarvi J., and Vahakangas K. J. Chromatogr. B 673 (1995) 97-105
15. Volosov A. J. Chromatogr. B 738 (2000) 419-425
16. Souppart C., Decherf M., Humbert H., and Maurer G. J. Chromatogr. B 762 (2001) 9-15
17. Levert H., Odou P., and Robert H. J. Pharm. Biomed. Anal. 28 (2002) 517-525
18. Bugamelli F., Sabbioni C., Mandrioli R., Kenndler E., Albani F., and Raggi M.A. Anal. Chim. Acta 472 (2002) 1-10
19. Maurer H.H., Kratzsch C., Weber A.A., Peters F.T., and Kraemer T. J. Mass Spectrom. 37 (2002) 687-692
20. Mandrioli R., Ghedini N., Albani F., Kenndler E., and Raggi M.A. J. Chromatogr. B 783 (2003) 253-263
21. Flesch G., Tudor D., Denouel J., Bonner J., and Camisasca R. Int. J. Clin. Pharmacol. Ther. 41 (2003) 299-308
22. Volosov A. Epilepsia 41 (2004) 1107-1111
23. Franceschi L., and Furlanut M. Pharmacol. Res. 51 (2005) 297-302
24. Brreton H., Cociglio M., Bressolle F., Peyriere H., Blayac J.P., and Hillaire-Buys D. J. Chromatogr. B 828 (2005) 80-90
25. Lanckmans K., Clinckers R., Van Eeckhaut A., Sarre S., Smolders I., and Michotte Y. J. Chromatogr. B 831 (2006) 205-212
26. Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L.A., and Stupp R. Clin. Cancer Res. 10 (2004) 3728-3736
27. Chelberg R.D., Gunawan S., and Treiman D.M. Ther. Drug Monit. 10 (1988) 188-193
28. Guidance for Industry, Bioanalytical Method Validation, FDA, 2001.
29. Patsalos P.N., Elyas A.A., and Zakrzewska J.M. Eur. J. Clin. Pharmacol. 39 (1990) 413-415
30. Guiso M.N., Rizzi G., Pirker S., Novak K., Czech T., Baumgartner C., Janigro D., Caccia S., and Vezzani A. Epilepsia 46 (2005) 1613-1619